REGENXBIO (NASDAQ:RGNX) Stock Price Up 6.2% – What’s Next?

REGENXBIO Inc. (NASDAQ:RGNX)’s share price traded up 6.2% during mid-day trading on Thursday . The stock traded as high as $11.61 and last traded at $11.6940. 488,947 shares changed hands during trading, a decline of 52% from the average session volume of 1,009,848 shares. The stock had previously closed at $11.01.

More REGENXBIO News

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Chardan Capital reaffirmed a “buy” on RGNX and set a $52 price target, signaling strong upside from current levels. Chardan Reaffirmation
• Neutral Sentiment: Zacks notes RGNX recently jumped on higher volume (a 5.4% move) but warns that recent downward earnings‑estimate revisions could limit near‑term upside; investors should watch subsequent analyst revisions. Zacks: Soars 5.4%
• Positive Sentiment: Leerink (reported by Yahoo Finance) called the earlier selloff “an overreaction” to the clinical hold, suggesting a recovery is possible if forthcoming safety data and disclosures calm investors. Leerink Commentary
• Negative Sentiment: The U.S. FDA placed clinical holds on RGX‑111 and RGX‑121 following identification of a tumor in a trial participant (disclosed in a Form 8‑K on Jan. 28), a direct driver of the recent sharp stock decline and operational uncertainty for those programs. FDA Clinical Hold / Form 8‑K
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Pomerantz) have launched investigations alleging potential disclosure gaps or securities claims tied to the FDA action, increasing legal and reputational risk. Levi & Korsinsky Investigation Pomerantz Investigation
• Negative Sentiment: Media coverage (Investing.com, AAII, MSN) documents a steep market reaction and broad selloff following the FDA notice; near‑term stock performance will hinge on company updates, the FDA’s path to lifting holds, and any further safety disclosures. Investing.com Coverage

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Leerink Partners lifted their target price on shares of REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective on shares of REGENXBIO in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a research report on Thursday, January 22nd. Barclays began coverage on REGENXBIO in a research report on Tuesday. They issued an “overweight” rating and a $37.00 price target for the company. Finally, Wall Street Zen lowered REGENXBIO from a “hold” rating to a “sell” rating in a report on Saturday. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $30.00.

REGENXBIO Trading Down 3.8%

The firm has a 50-day moving average of $13.72 and a two-hundred day moving average of $11.31. The firm has a market cap of $564.92 million, a price-to-earnings ratio of -3.22 and a beta of 1.07.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.18. REGENXBIO had a negative return on equity of 78.29% and a negative net margin of 110.29%.The company had revenue of $29.73 million for the quarter, compared to the consensus estimate of $24.41 million. As a group, equities analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in RGNX. AQR Capital Management LLC increased its stake in REGENXBIO by 2,247.7% during the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock valued at $4,437,000 after acquiring an additional 594,161 shares during the period. Assenagon Asset Management S.A. increased its position in shares of REGENXBIO by 64.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company’s stock valued at $16,709,000 after purchasing an additional 454,977 shares during the period. Invenomic Capital Management LP acquired a new position in shares of REGENXBIO in the third quarter valued at $4,120,000. Integral Health Asset Management LLC lifted its position in REGENXBIO by 57.1% in the third quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $10,615,000 after purchasing an additional 400,000 shares during the period. Finally, 22NW LP boosted its stake in REGENXBIO by 38.1% during the second quarter. 22NW LP now owns 923,679 shares of the biotechnology company’s stock worth $7,583,000 after buying an additional 255,000 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.